3billion
Financials
Valuation Metrics
3billion's Market Cap is ₩1512B. At end of 2025 it was ₩5801B. Ranked #1010 of 2,421 in KR market (top 42%), #510 of 1,640 on KOSDAQ (top 31%), #115 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 50%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 151.16B KRW | KR#1,010/2,421 Sec#115/231 |
| Revenue | 14.27B KRW | KR#2,224/2,421 Sec#166/231 |
| Net Income | 3.17B KRW | KR#1,339/2,421 Sec#93/231 |
| Total Assets | 58.71B KRW | KR#2,118/2,421 Sec#186/231 |
| Net Assets | 29.64B KRW | KR#2,180/2,421 Sec#196/231 |
| Employees | 85 | KR#1,769/2,421 Sec#144/231 |
| Value | ||
| P/E | 47.71x | KR#1,405/2,421 Sec#91/231 |
| P/B | 5.10x | KR#2,247/2,421 Sec#191/231 |
| P/S | 10.59x | KR#2,285/2,421 Sec#166/231 |
| FCF Yield | -3.87% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | 10.69% | KR#560/2,421 Sec#38/231 |
| ROA | 5.40% | KR#691/2,421 Sec#58/231 |
| Op. Margin | -39.65% | KR#2,205/2,421 Sec#158/231 |
| Revenue Growth | 102.85% | KR#83/2,421 Sec#17/231 |
| Financial Health | ||
| Debt Ratio | 98.08% | KR#1,545/2,421 Sec#176/231 |
| Total Debt | 5.06B KRW | KR#1,783/2,421 Sec#169/231 |
| FCF | -5.85B KRW | KR#1,532/2,421 Sec#121/231 |
| Cash | 9.09B KRW | KR#1,748/2,421 Sec#153/231 |
| Current Ratio | 1.29x | KR#1,415/2,421 Sec#148/231 |
| Performance | ||
| 1Y Return | -35.37% | KR#1,715/2,421 Sec#140/231 |
| 1M Return | -17.96% | KR#2,285/2,421 Sec#205/231 |
| From 52W High | -76.37% | KR#2,310/2,421 Sec#206/231 |
| 1Y MDD | -78.32% | KR#2,267/2,421 Sec#204/231 |
| Trading | ||
| Volume | 1,064,889 shares | KR#128/2,421 Sec#9/231 |
| Trading Value | 5.08B KRW | KR#362/2,421 Sec#35/231 |
| Foreign Own. | 12.18% | KR#406/2,421 Sec#31/231 |
| Per Share | ||
| EPS | 100 KRW | KR#1,421/2,421 Sec#94/231 |
| BPS | 931 KRW | KR#2,320/2,421 Sec#214/231 |
Company Info
3billion was established in 2016 to revolutionize rare disease diagnosis and treatment development using artificial intelligence, listing on KOSDAQ as a technology growth company in 2024. The company offers whole genome and whole exome-based rare disease diagnostic genetic testing services powered by AI genomic interpretation technology. By launching its genetic variant interpretation software 'GEBRA' as SaaS, 3billion is building an AI drug development platform based on accumulated data and expanding its technological competitiveness. 3billion is headquartered in Gangnam-gu, Seoul Metropolitan City.